Want to see FR:ALSEN full AI Analyst Report?
ALSEN Stock Chart & Stats
€0.40
€0.00(0.00%)
At close: 4:00 PM EST
€0.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.22 - €0.81
Previous CloseN/A
Volume61.80K
Average Volume (3M)540.27K
Market Cap
€133.96M
Enterprise Value€55.58M
Total Cash (Recent Filing)€47.46M
Total Debt (Recent Filing)€1.28M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Sep 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding515,448,600
10 Day Avg. Volume740,129
30 Day Avg. Volume540,266
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)2.28
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)€18.88M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityModest historical debt gives Sensorion flexibility to fund clinical programs without heavy fixed interest obligations. Over the next few months this reduces immediate solvency pressure, helps preserve optionality for licensing or partnering deals, and eases near-term refinancing risk.
Clinical-stage R&D Focus And Modality BreadthA focused pipeline targeting inner-ear disorders using both small molecules and gene therapy is a durable strategic asset. Multiple modalities diversify technical risk and enhance partnership appeal, supporting long-term value creation through trials, licensing milestones, or strategic alliances.
Historical Revenue Expansion (2020–2024)Prior revenue growth from collaborations demonstrates the company's ability to monetize R&D through partner funding and milestone recognition. That track record implies recurring partner interest is attainable, offering a durable non‑product revenue pathway if development progress resumes.
Bears Say
2025 Revenue Dropped To ZeroA complete revenue lapse in 2025 signals a structural disruption in collaboration income or milestone timing. Without recurring partner receipts, the company becomes more dependent on capital markets, heightening execution and financing risk over the next 2–6 months and beyond.
Sustained Negative Cash FlowLarge, persistent operating and free cash outflows create continuous funding needs. This entrenched cash burn makes the firm reliant on external financing or partner upfronts, increasing dilution and constraining R&D pacing and strategic choices during the coming quarters.
Large Operating And Net LossesMaterial operating and net losses reflect ongoing heavy investment without commercial revenues. Negative profitability depresses returns and equity value, forces recurring financings or asset sales, and raises structural sustainability questions for the business model absent successful partnerships or trial readouts.
Sensorion SAS News
ALSEN FAQ
What was Sensorion SAS’s price range in the past 12 months?
Sensorion SAS lowest stock price was €0.22 and its highest was €0.81 in the past 12 months.
What is Sensorion SAS’s market cap?
Sensorion SAS’s market cap is €133.96M.
When is Sensorion SAS’s upcoming earnings report date?
Sensorion SAS’s upcoming earnings report date is Sep 23, 2026 which is in 69 days.
How were Sensorion SAS’s earnings last quarter?
Sensorion SAS released its earnings results on Mar 18, 2026. The company reported -€0.04 earnings per share for the quarter, beating the consensus estimate of -€0.06 by €0.02.
Is Sensorion SAS overvalued?
According to Wall Street analysts Sensorion SAS’s price is currently Undervalued.
Does Sensorion SAS pay dividends?
Sensorion SAS does not currently pay dividends.
What is Sensorion SAS’s EPS estimate?
Sensorion SAS’s EPS estimate is -0.03.
How many shares outstanding does Sensorion SAS have?
Sensorion SAS has 515,448,600 shares outstanding.
What happened to Sensorion SAS’s price movement after its last earnings report?
Sensorion SAS reported an EPS of -€0.04 in its last earnings report, beating expectations of -€0.06. Following the earnings report the stock price went down -12.651%.
Which hedge fund is a major shareholder of Sensorion SAS?
Currently, no hedge funds are holding shares in FR:ALSEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sensorion SAS
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
ALSEN Stock 12 Month Forecast
Average Price Target
€1.00
▲(150.00% Upside)